United States · 
What does HighCape Partners invest in?
HighCape Partners invests most often at Series C and Series B (100% of the rounds on record), in sectors such as Life Sciences, Connected Health and Medical Device.
HighCape Partners highlights
- 01
3 rounds on record
- 02
Mostly Series C and Series B: 100% of its rounds
- 03
Sole investor in 1 rounds, median $5.0M
What they do
HighCape Capital is a growth equity fund created in 2013 by a group of highly experienced executives for the sole purpose of helping innovative Life Sciences companies transition from the initial stages of their business cycle into successful, thriving organizations.From their own website
- Type
- VC firm (from a list, unverified)
- Cheque size
- Not stated
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- Life SciencesConnected HealthMedical Device
- Based in
- Baltimore, United States
- Cold pitches
- Not accepted
The record
Every round we can evidence, newest first3 appearances
- 2017
2 rounds
- Sept
- Jun
- 2014
1 round
- Jun
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration2 named
KMKevin Matthew RakinManaging Member of General Partner of General PartneriFiling they signed
WMWilliam Matthew ZugaManaging Member of General Partner of General PartneriFiling they signed
We also hold 8 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$48Mgross assets of its fundsOct 2026
Exemptreporting adviserventure or small private funds
- Legal name
- Highcape Capital, L.P.
- SEC number
- CRD 170971
What they claim to have backed
From their own portfolio page (on their website)
6 of 6 we have independently watched raise
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.